Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

LWNVIVAT Limiting West Nile Virus impact by novel vaccines and therapeutics approaches

Coordinator
Fundacio Privada Institut De Recerca Sobre Immunopatologies-Caixa, Irsicaixa, Spain
Runs
1 December 2023 to 30 November 2027
Status
Running
EU funding
€5.8m
Total cost
€5.8m
Partners
8 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101137248

What the project is doing

In the project's own words, from its summary on CORDIS.

West Nile virus (WNV) is considered one of the most widespread mosquito-borne viral disease in the world. While most of WNV infected individuals are asymptomatic, 1% of WNV-infected individuals develop a severe illness that affects the central nervous system, causing encephalitis or meningitis and eventually the death. The case-fatality rate notoriously increases in immunosuppressed individuals and in population over 60 years old (up to 30%) and, to date, there is no prophylaxis or treatment for this disease.

Here, we aim to develop a safety prophylactic WNV vaccine that cover WNV diversity and protect elderly individuals by promoting the generation of potent and long-lasting neutralizing humoral and T cell responses, with limited or no cross-reactive activity against other flaviviruses. If success, the present proposal may guide the development of effective vaccines against other viruses, particularly flaviviruses. Methods: We will use outstanding computational tools to design novel Envelope-based immunogens that cover the global WNV genetic variability.

Immunogens will be designed for eliciting highly-specific neutralizing humoral responses, with limited potential to mediate antibody-dependent enhancement (ADE) of infection or disease. In addition, we will also seek for T cell responses that work synergistically with antibodies to generate a long-lasting and polyfunctional protective anti-WNV immune response. Besides a classical and highly effective recombinant protein-based vaccine approach, we will explore novel and innovative strategies based on Virus Like Particles, and the use of antibodies as adjuvants, that may improve vaccine immunogenicity and efficacy.

For immunogenicity analysis we have designed a complete set of assays that encompasses from in vitro testing, using human immune cells (tonsil and PBMCs) to in vivo evaluation using both young and old mice, and a complementary swine model.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Privada Institut De Recerca Sobre Immunopatologies-Caixa, IrsicaixaBarcelonaSpainCoordinator
Technische Universitaet BraunschweigBraunschweigGermanyParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Barcelona Supercomputing Center Centro Nacional De SupercomputacionBarcelonaSpainParticipant
Fundacio Centre De Regulacio GenomicaBarcelonaSpainParticipant
Hipra Scientific SLAmerSpainParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceThird party
Universite De MontpellierMontpellierFranceParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI